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OBJECTIVES: To describe medication utilization among newly diagnosed rheuma-
toid arthritis (RA) patients. METHODS: A retrospective analysis of administrative
claims identified individuals within a large manufacturing company with contin-
uous eligibility for a four-year time frame (2001-2008), using one year as a pre-index
period and 3 years for follow-up. New RA patients age 18-62 were identified as (1)
free of anymedical claimswith ICD9 code of 714.xxwith no biologic or non-biologic
disease modifying anti-rheumatic drugs (DMARDs) in pre-index year; (2) having at
least 2 separatemedical claimswith ICD9 code of 714.xx in the index year. The first
claim date was designated as the index date. Patients’ pharmacy claims for all
possible RA medications were followed for 3 years starting from the index date.
RESULTS: Among 1769 new RA patients in the study, 69% were females. Average
agewas 55 in the index year. During the index year, 30% (N521) of patients started
biologic or non-biologic DMARD treatment, 56% (N985) received painmedications
but no DMARDs, and 14% (N263) did not have prescriptions for either DMARDs or
painmedications. However, in year 3, 25% (N444) received DMARDs, 47% (N838)
received pain medications only, and 28% (N487) did not have prescriptions for
either. Among 521who started DMARD treatment in Year 1, 71% (N368) remained
on DMARDs in Year 2, and 58% (N300) remained on DMARDs for all 3 years.
CONCLUSIONS: In the first 3 years of onset of RA, 25-30% of patients received
biologic or non-biologic DMARD treatments in each year. Most patients starting
DMARDs stay on treatment for multiple years. A substantial portion of patients,
however, do not remain on DMARD treatment. This demonstrates that unmet
needs may remain with currently available biologic and non-biologic DMARDs.
Future research should differentiate utilization patterns of biologic and non-bio-
logic DMARDs.
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ANALYZING THE DIFFERENCE IN HEALTH CARE COSTS OF RHEUMATOID
ARTHRITIS PATIENTS SWITCHING OR DOSE ESCALATING ANTI-TNF BIOLOGICS
USING COMBINED PROPENSITY SCORE MATCHING AND MULTIVARIATE
REGRESSION MODEL
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OBJECTIVES: To compare anti-tumor necrosis factor biologic (anti-TNF) dose esca-
lation vs. switching in matched rheumatoid arthritis (RA) patient populations.
METHODS: Adult RA patients (ICD-9: 714.XX) treated with anti-TNFs were identi-
fied from a US claims database (6/2004-6/2009). Patients who switched therapy or
escalated their dose were identified between the anti-TNF index date and June
2008. All-cause and RA-related health care costs were calculated during the 12-
months after switch or dose escalation. To arrive at comparable populations, pro-
pensity score matching (PSM) followed by generalized linear regression models
(GLM) were employed. PSM does not assume any specific relationship between
outcome and covariates, therefore, GLMs with gamma distribution and log link
were applied to the matched sample to further adjust for any remaining bias.
RESULTS: Among 2587 eligible patients, 1229 switched to another anti-TNF and
1358 escalated their dosage. In the unadjusted sample, all-cause and RA-related
healthcare costs were significantly lower for patients that switched therapy. After
adjusting for baseline differences with PSM, all-cause and RA-related total health
care costs, including medication, were not statistically different for switchers ver-
sus dose escalators (All-cause: $32,959 vs. $34,225, p0.19; RA-related: $19,447 vs.
$20,130,p0.17). When GLM was applied over the matched PSM population to ad-
just for remaining differences, all-cause healthcare costs were not statistically
different but RA-related costs were significantly higher for those that switched
therapies versus those that dose escalated (All-cause; $32,493 vs. $31,885, p0.48;
RA-related: $20,341 vs. $17,667, p0.01). CONCLUSIONS: Using a combined PSM/
GLM model, for RA-related costs, conclusions comparing switching therapy vs.
dose escalating therapy completely reverse once patient populations are properly
adjusted, such that dose escalating is less costly in matched patients. This dem-
onstrates the importance of adjusting for differences in anti-TNF treated popula-
tions in comparative effectiveness research.
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OBJECTIVES: To characterize patients with rheumatoid arthritis (RA), psoriatic ar-
thritis (PsA), and ankylosing spondylitis (AS) initiating golimumab (GLM) and to
analyze GLM utilization. METHODS: Data were from the MarketScan® Research
Database. Inclusion criteria were diagnosed RA, PsA, or AS, aged 18 years at first
diagnosis, a GLM claim between April 24, 2009 and December 31, 2010, and contin-
uous enrollment with 6-months prior and 3-months after first GLM claim.
RESULTS: Of the 1732 GLM patients analyzed, 1215 were diagnosed with RA, 375
with PsA, and 142 with AS. The most common co-morbidities were osteoarthritis
(51.1%), hypertension (44.8%), hyperlipidimia (27.8%), depressive disorders (20.0%),
and gastroesophogeal reflux disease (GERD; 18.5%). Of GLM patients 431 (24.9%)
were naïve to biologics (bio-naïve), and 1301 (75.1%) had previous biologic experi-
ence (bio-experienced). Bio-experienced patients had prior experience with etan-
ercept (57.2%), adalimumab (53.4%), infliximab (24.4%), abatacept (11.3%), and other
biologics (7.1%). Of patients with 2 refills of 28-31 day supply of GLM (n1101),
mean  SD number of days between all fills was 33.7  15.6 days with a median of
30 days. There was no dosing difference between bio-naïve and bio-experienced
patients. The majority of patients (81.3%) filled their drug within the 21-38 day
compliance window; 1.9% filled within 20 days and 16.8% filled outside the 38 day
window. Among patients with 12 months of data after initiating GLM (n347),
switching rate to another biologic therapy in the study period was 23.2% among
bio-naïve and 38.5% among bio-experienced. CONCLUSIONS: In this analysis, the
majority of GLMpatients are bio-experienced andhave switchedmainly fromother
anti-TNFs. Observed refill patterns of GLM are consistent with labeled every four
week dosing.and were similar for bio-naïve and bio-experienced patients. Bio-na-
ïve patients, however, are less likely to switch to another biologic during the 12-
month period post initiating GLM than bio-experienced patients.
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MODELING FUTURE PREVALENCE OF ARTHRITIS AND DEMAND FOR
PHARMACEUTICALS
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OBJECTIVES: Accurately forecasting future disease prevalence and resulting de-
mand for pharmaceuticals requires modeling changes in demographics, economic
considerations, health care policy, disease risk factors, and treatment options. This
study forecasts future arthritis prevalence and related use of prescribed
medications. METHODS: Using a microsimulation approach, we model future
arthritis prevalence and pharmaceutical use for each person in a stratified ran-
dom sample of the US population. The population database combines 1) popu-
lation and economic data from the American Community Survey; 2) health
status and disease risk factors from the Behavioral Risk Factor Surveillance
System; and 3) patient health data from National Nursing Home Survey. Logistic
regression analysis with the Medical Expenditure Panel Survey models the pro-
pensity of people with arthritis to use prescribed medications for arthritis. Fore-
casts through 2030 consider trends in household income and demographics.
One scenario models expansion of medical coverage under the Affordable Care
Act (ACA). RESULTS: In 2010, 47.1 million people (15% of US population) had diag-
nosed arthritis. Of these, 56% used prescription medications to treat their condi-
tion. The Medicare population comprised 46% of the population with arthritis, but
50%of patients takingmedications for arthritis. Between 2010 and 2030 the number
of people with arthritis will grow by 28%, but the number taking prescribed medi-
cation for arthritis will grow by 25%. An estimated 13% of the population with
arthritis is uninsured, and a portion of this population will become insured in 2014
under the ACA, causing an 11.6% increase in the use of prescribedmedicines in this
population. CONCLUSIONS: Prevalence rates for diagnosed and treated arthritis
are projected to grow at similar rates over the next 20 years. The implementation of
the ACA will increase the number of persons utilizing pharmaceutical treatment
for arthritis by 1.6%.
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OBJECTIVES: Many types of pain medications are commonly used in treating os-
teoarthritis (OA). The purpose of this study was to identify the demographic and
clinical factors associated with the choice of painmedications between duloxetine
and other pharmacological agents among OA patients.METHODS: A retrospective
cohort study was conducted using a claims database. OA patients who initiated
duloxetine, anticonvulsants, antidepressants, muscle relaxants, non-steroidal an-
ti-inflammatory drugs (NSAIDs), opioids, or steroids from November 1, 2010 to
March 31, 2011 were selected. The dispense date of the first initiated medication
preceded by at least a 90-day gap in medication supply was defined as the index
date. Comorbidities and prior medication use was assessed during 6 months prior
to the index date. Multiple logistic regression models were performed to identify
predictors of initiating duloxetine versus other pain medication. Models were es-
timated with different sets of predictors: 1) Charlson comorbidity index (CCI) score
and use of selected medications, and 2) individual comorbidities and number of
unique pain medications in the prior six months, respectively. RESULTS:We iden-
tified 96,666 OA patients (mean age 65.2 years; 64.5% female) who initiated opioids
(41.6%), NSAIDs (21.8%), steroids (15.4%), muscle relaxants (7.7%), antidepressants
(7.5%), anticonvulsants (3.9%), or duloxetine (2.1%). Patients who initiated anticon-
vulsants and duloxetine had the highest CCI scores, were onmoremedications and
had more inpatient stays prior to initiation than patients initiating other medica-
tions. Males were in general less likely to initiate duloxetine than the other medi-
cations. Higher CCI (except for comparing with anticonvulsants) score and prior
use of pregabalin, gabapentin, antidepressants, muscle relaxants, and steroids
were associated with a higher likelihood of initiating duloxetine. Patients who had
more than 10 unique medications, depression, or anxiety were more likely to ini-
tiate duloxetine. CONCLUSIONS: Presence of selected demographics, comorbidi-
ties and prior use ofmedicationswere associatedwith duloxetine initiation among
OA patients.
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